ABSTRACT
Bayesian methods are being increasingly used in the design and analysis of clinical trials. Chen and Kim (2009) presented Bayesian analyses of melanoma data from a clinical trial conducted by Eastern Cooperative Oncology Group
models. et al. (2002) explored a Bayesian approach to the design, analysis and interpretation of Phase II clinical trials conducted at the National Cancer Centre in Singapore on the activity of Gemcitabine in patients with metastatic nasopharyngeal carcinoma. Connor and Berry (2005) used Bayesian methods to analyze adverse event data from medical device clinical trials.
